-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., an innovative pharmaceutical holding subsidiary of the company, is carrying out a randomized, double-blind, placebo-controlled clinical trial (GST-peak-triple) to evaluate the safety and efficacy of the triple full oral administration plan (GST-HG141+GST-HG131+ NAS nucleoside (acid)) in patients with chronic hepatitis B virus (GST-Peak-Triple). The first trial participants were successfully enrolled and administered.

Zhitongcaijing·09/04/2026 10:33:15
Listen to the news
Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., an innovative pharmaceutical holding subsidiary of the company, is carrying out a randomized, double-blind, placebo-controlled clinical trial (GST-peak-triple) to evaluate the safety and efficacy of the triple full oral administration plan (GST-HG141+GST-HG131+ NAS nucleoside (acid)) in patients with chronic hepatitis B virus (GST-Peak-Triple). The first trial participants were successfully enrolled and administered.